+------------------------------------------------------------------------------+
BN 03/26 13:49 *FINK SAYS HE EXPECTS TO SEE MORE STIMULUS FROM ECB BFW 03/26 13:48 *FINK SAYS EUROPE IS MUCH IMPROVED POSITON; DRAGHI OUTSTANDING BN 03/26 13:47 *BLACKROCK'S FINK SEES IMPROVEMENTS IN PERIPHERAL EUROPE BN 03/26 13:47 *FINK SAYS EUROPE IS MUCH IMPROVED POSITON; DRAGHI OUTSTANDING BN 03/26 13:41 *FINK SAYS MORE VOLATILITY AHEAD; MORE RELIANCE ON GOVT. POLICY BN 03/26 13:36 *FINK SAYS MEXICO IS DOING FINE; LEADERSHIP IS HELPING ECONOMY BN 03/26 13:24 *FINK SAYS REGULATION WILL MAKES BANKS BETTER; SOUNDER SAFER BN 03/26 13:24 *FINK SAYS BANKS SHOULD BE TRADING AT HIGHER PE MULTIPLES BN 03/26 13:13 *FINK SAYS WASHINGTON GUILTY OF NOT PROVIDING LONG-TERM THINKING BN 03/26 13:11 *FINK SAYS COMPANIES COULD REINVEST MORE; FOCUS ON LONG-TERM BN 03/26 13:09 *BLACKROCK'S FINK TALKS ABOUT LETTER SENT TO S&P 500 COMPANIES BN 03/26 13:08 *BLACKROCK'S FINK SPEAKS ON FOX BUSINESS WITH BARTIROMO
+------------------------------------------------------------------------------+
*FINK SAYS HE EXPECTS TO SEE MORE STIMULUS FROM ECB 2014-03-26 13:49:43.840 GMT
--JULIE ALNWICK
-0- Mar/26/2014 13:49 GMT
+------------------------------------------------------------------------------+
*SUEDZUCKER ADDED TO CONVICTION SELL LIST AT GOLDMAN SACHS 2014-03-26 13:48:40.92 GMT
--JOSHUA FINEMAN
-0- Mar/26/2014 13:48 GMT
+------------------------------------------------------------------------------+
BN 03/26 13:10 *SAP ACQUISITION IS SAID TO BE VALUED AT AT LEAST $1 BILLION
+------------------------------------------------------------------------------+
*SAP IS SAID TO PLAN ACQUISITION ANNOUNCEMENT AS EARLY AS TODAY 2014-03-26 13:10:37.975 GMT
--KENNETH WONG
-0- Mar/26/2014 13:10 GMT
Select battery related names pulling back: PLUG -5.7%, CPST -3.8%, BLDP -3.7%, FCEL -3.4%.
A few financial names are trading lower: RBS -2%, LYG -1.6% (continued weakness)
Other news: GGS -63.8% (files voluntary Chapter 11 petitions to facilitate financial restructuring), INSM -30.1% (announces results from Phase 2 clinical trial for treatment resistant nontuberculous mycobacterial lung infections; ARIKAYCE did not meet the pre-specified level for statistical significance, however, ARIKAYCE did achieve statistical significance with regard to the clinically relevant key secondary endpoint of culture conversion), EXEL -22.4% (provides update on ongoing COMET-1 Phase 3 Pivotal trial in men with metastatic castration-resistant prostate cancer), GCA -18% ( announces that its cash access agreements with Caesars Entertainment will not be renewed; reaffirms adjusted EBITDA and cash EPS estimates for FY14 ), BFAM -5.4% (announces secondary offering of 7 mln shares of common stock by selling stockholders), SZYM -2.6% (announces proposed offering of $100 mln of convertible senior subordinated notes due 2019 and 5 mln shares of common stock in separate offerings), VEEV -2.1% (prices offering of 12 mln shares of common stock at a price to the public of $26.35 per share by co and selling shareholders), CCL-1.4% (following yesterday's earnings), ESS -1.1% (announces sale of 450,000 shares of common stock under equity distribution agreement), ECYT -1.1% (files mixed securities shelf offering; announces proposed offering of 4.5 mln shares of its common stock; announces proposed offering of 4.5 mln shares of its common stock), ZNGA -0.8% (following FB news), BYI -0.7% (following IGT guidance), BID -0.6% ( issues response to Third Point litigation: 'Continues to believe that the Board's decisions to adopt and maintain the 12-month rights plan are both valid and legal' ), GSK -0.2% (withdraws its MAA to the European Medicines Agency for the use of Mekinist (trametinib) in combination with previously approved BRAF inhibitor Tafinlar (dabrafenib) for treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation).
Analyst comments: TEF -1.4% (ticking lower; downgraded to Underperform from Neutral at BofA/Merrill), ACI -0.6% and CNX -0.4% (downgraded to Neutral from Buy at UBS), HME -0.3% (downgraded to Neutral from Buy at Citigroup)